Skip to content

Compare U.S. Stocks

Put up to three companies side by side on valuation, growth, profitability, and debt.

Compare within a sector
MetricABVXAbivax SAGMABGenmab A/SINCYIncyte
Snapshot
Price$116.74$33.65$128.31
Market cap$11.63B$16.18B$23.35B
Valuation
P/E—20.9x17.7x
Forward P/E—27.9x12.6x
Growth
Revenue growth—20.7%21.5%
EPS growth—-25.3%2455.3%
Profitability
Net margin—21.1%26.7%
ROE-51.7%14.5%29.2%
Balance sheet & cash
Debt / equity0x0.93x0.01x
Free cash flow yield-2.1%—2.2%
Dividend yield———
Verdict
Investment ratingWeak· 35Favorable· 62Strong· 86

5-Year Price Projections

Base case

Projected using each stock's current EPS, growth rate (EPS or revenue growth), and P/E ratio. P/E assumed to compress 25% on the low end and remain steady on the high end. Not a forecast — for comparative analysis only.

YearABVXtoday $117GMABtoday $34INCYtoday $128
2027$93.68 – $137.40+18% CAGR$25.74 – $37.76+12% CAGR$2,459.04 – $3,606.59+2711% CAGR
2028$100.24 – $147.02+12% CAGR$26.26 – $38.51+7% CAGR$62,836.06 – $92,159.56+2580% CAGR
2029$107.26 – $157.31+10% CAGR$26.78 – $39.28+5% CAGR$1,605,656.17 – $2,354,962.38+2538% CAGR
2030$114.77 – $168.32+10% CAGR$27.32 – $40.07+4% CAGR$41,029,492.63 – $60,176,589.19+2517% CAGR
2031$122.80 – $180.11+9% CAGR$27.86 – $40.87+4% CAGR$1,048,430,728.12 – $1,537,698,401.25+2504% CAGR
5-yr CAGR1.0% – 9.1%-3.7% – 4.0%2312.4% – 2504.5%